The ubiquitin system is complex, multifaceted, and is crucial for the modulation of a vast
number of cellular processes. Ubiquitination is tightly regulated at different levels by a range …

Proteasome inhibitors are one of the most important classes of agents to have emerged for
the treatment of multiple myeloma in the past two decades, and now form one of the …

Targeting the ubiquitin-proteasome pathway has emerged as a rational approach in the
treatment of human cancer. Based on positive preclinical and clinical studies, bortezomib …

Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is responsible for the
regulation of a large number of genes that are involved in important physiological …

Genomic alterations may make cancer cells more dependent than normal cells on
mechanisms of proteostasis, including protein folding and degradation. This proposition is …

Use of proteasome inhibitors (PIs) has been the therapeutic backbone of myeloma treatment
over the past decade. Many PIs are being developed and evaluated in the preclinical and …

The endoplasmic reticulum (ER) is a multifunctional organelle required for lipid biosynthesis,
calcium storage, and protein folding and processing. A number of physiological and …

Over the past ten years, proteasome inhibition has emerged as an effective therapeutic
strategy for treating multiple myeloma (MM) and some lymphomas. In 2003, Bortezomib …

Activation of nuclear factor (NF)-κB, one of the most investigated transcription factors, has
been found to control multiple cellular processes in cancer including inflammation …

In patients with multiple myeloma (MM), risk stratification by chromosomal abnormalities may
enable a more rational selection of therapeutic approaches. In the present study, we …